How big is ACADIA Pharmaceuticals, Inc.?

As of Jun 18, ACADIA Pharmaceuticals, Inc. has a market capitalization of $3.82 billion, with net sales of $996.28 million and a net profit of $228.89 million over the latest four quarters.

As of Jun 18, ACADIA Pharmaceuticals, Inc. has a market capitalization of 3,815.85 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 996.28 million for the latest four quarters, alongside a net profit of 228.89 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds amounting to 732.79 million and total assets of 1,187.76 million.

What does ACADIA Pharmaceuticals, Inc. do?

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for central nervous system disorders, with a recent market cap of approximately $3.82 billion and net sales of $244 million. The company has a P/E ratio of 16.00 and no dividend yield.

Overview:<BR>ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 244 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 19 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,815.85 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.88 <BR>Return on Equity: 29.91% <BR>Price to Book: 4.99 <BR><BR>Contact Details:<BR>Address: 3611 Valley Centre Dr Ste 300, SAN DIEGO CA: 92130-3331 <BR>Tel: 1 858 5582871 <BR>Fax: 1 858 5582872 <BR>Website: http://www.acadia-pharm.com/

Who are in the management team of ACADIA Pharmaceuticals, Inc.?

As of March 2022, the management team of ACADIA Pharmaceuticals, Inc. includes Dr. Stephen Biggar (Independent Chairman), Mr. Stephen Davis (CEO), and several independent directors: Ms. Elizabeth Garofalo, Mr. Julian Baker, Ms. Laura Brege, Mr. James Daly, and Dr. Edmund Harrigan. They oversee the company's strategic direction and operations.

As of March 2022, the management team of ACADIA Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Stephen Biggar, Independent Chairman of the Board<BR>- Mr. Stephen Davis, Director and Chief Executive Officer<BR>- Mr. Elizabeth Garofalo, Director<BR>- Mr. Julian Baker, Independent Director<BR>- Ms. Laura Brege, Independent Director<BR>- Mr. James Daly, Independent Director<BR>- Dr. Edmund Harrigan, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Should I buy, sell or hold ACADIA Pharmaceuticals, Inc.?

Is ACADIA Pharmaceuticals, Inc. overvalued or undervalued?

As of August 6, 2025, ACADIA Pharmaceuticals is considered attractive but overvalued compared to peers, with a P/E ratio of 16 and strong one-year returns of 51.59%, although it lags behind the S&P 500's three-year return of 70.41%.

As of 6 August 2025, the valuation grade for ACADIA Pharmaceuticals, Inc. has moved from very attractive to attractive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 16, an EV to EBIT of 34.05, and an EV to EBITDA of 29.59, which are higher than some of its peers, such as Exelixis, Inc. with a P/E of 15.81 and Alkermes Plc with an EV to EBITDA of 9.41.<BR><BR>In comparison to the S&P 500, ACADIA has shown strong one-year returns of 51.59%, significantly outperforming the index's 17.14%. However, over a three-year period, it lags behind the S&P 500, which returned 70.41%, indicating potential concerns about long-term growth. Overall, the current valuation suggests that investors may be paying a premium for ACADIA Pharmaceuticals, Inc. relative to its peers and historical performance.

Is ACADIA Pharmaceuticals, Inc. technically bullish or bearish?

As of September 12, 2025, ACADIA Pharmaceuticals has a mildly bullish trend, supported by positive weekly and monthly MACD indicators and strong year-to-date performance of 34.90%, despite some caution from a mildly bearish KST and underperformance in the 3- and 5-year periods.

As of 12 September 2025, the technical trend for ACADIA Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, and the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, while the Bollinger Bands show a bullish stance on the weekly and mildly bullish on the monthly. However, the KST is mildly bearish on the weekly, which introduces some caution. <BR><BR>In terms of performance, ACADIA has outperformed the S&P 500 on a year-to-date basis with a return of 34.90% compared to the S&P 500's 12.22%, and it has also significantly outperformed over the past year with a return of 51.59% versus 17.14%. However, over the longer term, it has underperformed the S&P 500 in both the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, supported by several positive indicators, but tempered by mixed signals in some areas.